A systematic review of the budget impact analyses for antitumor drugs of lung cancer
- PDF / 1,338,239 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 88 Downloads / 178 Views
Cost Effectiveness and Resource Allocation Open Access
REVIEW
A systematic review of the budget impact analyses for antitumor drugs of lung cancer Lu Han1†, Xin Zhang1†, Wen‑Qi Fu1, Cheng‑Yao Sun1, Xian‑Ming Zhao2, Liang‑Ru Zhou1 and Guo‑Xiang Liu1*
Abstract Background: Budget impact analyses (BIAs) are used for reimbursement decisions and drug access medical insur‑ ance, as a supplement to cost-effectiveness analyses (CEAs). Objectives: We systematically reviewed BIAs for antitumor drugs of lung cancer to provide reference for high-value drug budget impact analyses and decision making. Methods: We conducted a literature search on PubMed, EMbase, The Cochrane Library, China National Knowledge Infrastructure and Wanfang Data Knowledge Service Platform from 2010 to 2019. The methodological indicators and result information of the budget impact analyses were extracted and evaluated for quality. Results: A total of 14 studies on the budget impact for antitumor drugs of lung cancer were included, and the over‑ all quality was good. Half of studies were from developed countries. Nine of the studies were designed using the BIA cost calculation model, and two were simulated using the Markov model Monte Carlo model. From all studies, only 14.3% reported model validation. The budget impact results of the same drug in different countries were inconsistent. Conclusions: Included studies evaluating budget impact analyses for anti-tumor drugs of lung cancer showed vari‑ ability in the methodological framework for BIAs. The budget impact analyses of high-value drugs need to be more stringent to ensure the accuracy of the parameters, and should provide reliable results based on real data to decisionmaking departments, which should carefully consider access to lung cancer drugs. Keywords: Budget impact analyses, Antitumor drugs, Lung cancer Background Lung cancer is the most frequent cancer and the leading cause of cancer death among males. According to the Global cancer statistics 2018, lung cancer is the most common diagnosed cancer accounting for 11.6% of the total cases, and the leading cause of cancer death accounting for 18.4% of the total cancer deaths worldwide. In 2018, there were estimated to be 2.1 million new lung cancer cases and 1.8 million deaths [1]. Meanwhile, lung cancer had the highest economic cost with *Correspondence: [email protected] † Lu Han and Xin Zhang contributed equally to this work 1 School of Health Management/Public Health, Harbin Medical University, Harbin 150081, China Full list of author information is available at the end of the article
€18·8 billion, 15% of overall cancer costs in the European Union [2]. The World Health Organization (WHO) divides lung cancer into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) based on its biology, therapy, and prognosis [3, 4]. NSCLC includes two major types that account for more than 80% of total lung cancer cases: non-squamous cell, including adenocarcinoma, large cell carcinoma, and other cell types; and squamous cell (epidermoi
Data Loading...
